| Literature DB >> 33869822 |
Esraa Ahmed Mohamed El-Bondkly1, Alaa Ahmed Mohamed El-Bondkly2, Aya Ahmed Mohamed El-Bondkly3.
Abstract
The growing threat arises due to diseases such as cancer and the infections around the world leading to a critical requirement for novel and constructive compounds with unique ways of action capable of combating these deadly diseases. At present, it is evident that endophytic fungi constitute an enormous as well as comparatively untapped source of great biodiversity that can be considered as a wellspring of effective novel natural products for medical, agricultural and industrial use. Marine endophytic fungi have been found in every marine plants (algae, seagrass, driftwood, mangrove plants), marine vertebrates (mainly, fish) or marine invertebrates (mainly, sponge and coral) inter- and intra-cellular without causing any palpable symptoms of illness. Since evolution of microbes and eukaryotes to a higher level, coevolution has resulted in specific interaction mechanisms. Endophytic fungi are known to influence the life cycle and are necessary for the homeostasis of their eukaryotic hosts and the chemical signals of their host have been shown to activate gene expression in endophytes to induce expression of endophytic secondary metabolites. Marine endophytic fungi are receiving increasing attention by chemists because of their varied and structurally unmatched compounds that have strong biological roles in life as lead pharmaceutical compounds, including anticancer, antiviral, insulin mimetic, antineurodegenerative, antimicrobial, antioxidant and immuno-suppressant compounds. Moreover, fungal endophytes proved to have different biological activities for exploitation in the environmental and agricultural sustainability.Entities:
Keywords: Applications; Fungi; Marine endophytic; Medical; Metabolites; Pharmaceutical
Year: 2021 PMID: 33869822 PMCID: PMC8035529 DOI: 10.1016/j.heliyon.2021.e06362
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Figure 1Marine pharmaceuticals their sources and chemical classes.
List of clinical and natural products isolated from marine sources with potential drugs applications.
| Medical status | Compound name | Structural class | Molecular Target | Host | Disease area |
|---|---|---|---|---|---|
| Approved | Cytarabine, Ara-C | Nucleoside | DNA polmerase | Sponge | Cancer (Leukemia) |
| Viderabine, Ara-A | Nucleoside | Viral DNA polymerase | Sponge | Antivirals (Herpes simplex) | |
| Ziconotide | Peptide | N-type Ca chanel | Snall | Ache (Chronic pain) | |
| Eribulin Mesylate (E7389) | Macrolide | Microtubules | Sponge | Sarcoma (breast cancer and liposarcoma) | |
| Citarabine | Alkaloid | Inhibition of DNA synthesis | Sponge | Leukemia (acute non-lymphoblastic) | |
| Omega-3-acid ethyl esters (Lovaza®) | Omega-3 fatty acids | Trygliceride-synthesizing enzymes | Fish | Hypertriglyceridemia (Pancreatitis) | |
| Trabectedin (ET-743) | Alkaloid | Minor groove of DNA | Tunicate | Malignance (Breast, prostate, and paediatric sarcomas) | |
| Eribulin (E7389) | Polyketide | Inhibition of growth phase of microtubules without a_ecting the shortening phase and sequesters tubulin into nonproductive aggregates | Advanced solid tumors, breast | ||
| Phase IV | Actinomycin/ | Peptide | Inhibition of RNA polymerase | Childhood cancer, Wilms tumor | |
| Phase III | Brentuximab vedotin (SGN-35) | Antibody drug conjugate (MM auristatin E) | CD30 & microtubules | Mollusk | Sarcoma (Hodgkin lymphoma) |
| Phase III | AE-941/ | Peptide | Inhibition of gelatinolytic and elastinolytic activities of MMP-2, MMP-9, and MMP-12. | Shark cartilage | Renal, lung cancer |
| Phase II | Plitidepsin (Aplidin®) | Depsipeptide | Rac1 & JNK activation | Tunicate | Cancer (Acute lymphoblastic leukemia) |
| Dolastatin 10/ | Peptide | Inhibition of microtubules and pro-apoptotic e_ects | Pancreatic cancer | ||
| DMXBA (GTS-21) | Alkaloid | α7 nicotinic acetylcholine receptor | Worm | Cognition/Schizophrenia (Alzheimer's disease) | |
| Plinabulin (NPI-2358) | Diketopiperazine | Microtubules and JNK stress protein | Fungus | Sarcoma (Non-small-cell lung carcinoma) | |
| Elisidepsin (Irvalec®) | Depsipeptide | Plasma membrane fluidity | Mollusk | Tumor (Breast, colon, pancreas, lung, and prostate cancer) | |
| Aplidine | Peptide | Induce the apoptotic cascade | Leukemia Non Hodgkin Lymphoma | ||
| PM1004 (Zalypsis®) | Alkaloid | DNA-binding | Nudibranch | Tumor (Solid human tumors and hematological malignancies) | |
| Eribulin (E7389) | Polyketide | Lissodendoryx sp. | Advanced solid tumors, breast | Activation of cellular apoptosis under anchorage-independent and -dependent cell culture conditions | |
| CDX-011 Marizomib | Antibody drug conjugate (MM auristatin E) | Glycoprotein NMB & microtubules | Mollusk | Tumor (Breast cancer) | |
| Bryostatin-1/ | Polyketide | Inhibition of growth and alteration of di_erentiation | Metastatic solid tumors | ||
| Phase I | (Salinosporamide A: NPI-0052) | Beta-lactone- lactam gamma | 20S proteasome | Bacterium | Sarcoma (Multiple myeloma) |
| PM01183 | Alkaloid | Minor groove of DNA | Tunicate | Sarcoma (Myeloid leukemia cells) | |
| Kahalalide F | /Peptide | Induction of changes in lysosomal membrane | Prostate cancer | ||
| SGN-75 | Antibody drug Conjugate (MM Auristatin F) | CD70 & microtubules | Mollusk | Sarcoma (Renal cell carcinoma) | |
| PM02734/e | Peptid | Antiproliferative | Breast, colon, pancreas, lung and prostate | ||
| ASG-5ME | Antibody drug Conjugate (MM) Auristatin E) | ASG-5 & microtubules | Mollusk | Sarcoma (Pancreatic, prostate and gastric cancers) | |
| Hemiasterin (E7974) | Tripeptide | Microtubules | Sponge | Sarcoma (Antimitotic and antineoplastic) | |
| Bryostatin 1 | Polyketide | Protein kinase | Bryozoa | Sarcoma (Anti-AIDS/HIV) | |
| Salinosporamide A (Marizomib®) | /Polyketide | Prevention of proteins breakdown involved in signal transduction, which blocks the cancer cells growth and survival | |||
| Pseudopterosins | Diterpene glycoside | Elcosanoid metabolism | Soft coral | Wound healing (Anti-inflammatory and analgesic activity) |
Figure 2Distribution of marine-derived fungal endophytes and isolation rate among different marine sources.
Figure 3Distribution ratio of different chemical metabolites in endophtic natural products obtained from marine fungal endophytes.
Figure 4Secondary metabolites from marine fungal endophytes of algae.
Figure 5Secondary metabolites from marine fungal endophytes of sponge.
Figure 6Secondary metabolites from marine fungal endophytes of corals.
Figure 7Secondary metabolites from marine fungal endophytes of mangrove.